High-Level Assessment of a Late-Stage Asset in Oncology

A midsize pharma company was in initial discussions regarding the acquisition of a potential therapeutic target. They were interested in a quick and high-level assessment of the asset, asking for Blue Matter’s specific perspectives on the size of the opportunity and its position in the treatment paradigm to make an initial go/no-go decision on the deal.

Blue Matter conducted secondary research to outline the target’s place in the treatment paradigm, unmet needs, clinical development plan (CDP), comparison to other CDPs in similar indications, and the potential size of the market opportunity. Our secondary research also highlighted potential risks that needed to be validated via primary market research and further diligence. We summarized these insights and recommendations in an executive level presentation that drove the go/no-go decision on the deal.

Based on our findings and recommendations, the client team decided not to move forward with an offer to acquire the target.